Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Deal For Biogen, But Not The One Investors Are Waiting For

Executive Summary

The firm announced a small deal with Karyopharm for a preclinical asset with potential in ALS, but large deals are also being considered, management told the fourth quarter earnings call.

Advertisement

Related Content

TMS Stroke Deal Suggests No Big Buy From Biogen Yet
Biogen's Spinraza Sales Plateau; The Challenge Is Keeping Up With The Successful Launch
Biogen Re-Ups With Ionis In Search Of A Neuroscience 'Innovation Engine'
Sanofi Builds Blood Disorder Specialty With Bioverativ Buy
J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
A Year To Remember For US Drug Launches
Biogen Builds Out Neuroscience Niche With Ischemic Stroke Drug
Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy
Biogen Forecasts Gradual Launch For Life-Transforming Drug Spinraza
Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100272

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel